Rajyalakshmi Luthra

University Of Tx Md Anderson Can Ctr

$291,397

Attributed

$1,165,587

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $341K · FY2018–23

$500K$375K$250K$125K$0

'18

'19

'20

'21

'22

'23

Funding mix

By agency

NIH$1,165,587 · 2

By mechanism

UH3$787,854 · 1

UH2$377,733 · 1

Top collaborators

Most similar at University Of Tx Md Anderson Can Ctr

Same institution · by research overlap

Leland Hu$3,569,147
Moran Amit$4,840,424
Albert Koong$7,304,561
Scott Kopetz$13,199,822
Michael Kupferman$540,000

Others in their field

Other Emerging Leaders on “Colon Carcinoma”

Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
Leonard Freedmand · Leidos Biomedical Research, Inc.$5,700,376
Shannon Jones McCall · Duke University$4,953,390
Nicholas Arpaia · Columbia Univ New York Morningside$4,949,940
Xingyi Guo · Vanderbilt University Medical Center$4,610,997
James Gregory Caporaso · Northern Arizona University$3,976,398

Research focus

Colon CarcinomaAdvisory CommitteesBehaviorColon Cancer PatientsBevacizumabBiological MarkersBiologyCancer And Leukemia Group BAssay DevelopmentCessation Of LifeCetuximabCharacteristicsChemotherapyClassificationClia CertifiedClinicClinical BiomarkersClinical ChemistryBenefits And RisksClinical TrialsCohortCollaborationsColon AdenocarcinomaColorectal Cancer

Grant awards (5)

Colorectal Cancer Molecular Subtype Assay Development and Validation$149,772

UH3 · FY2023 · CA

Colorectal Cancer Molecular Subtype Assay Development and Validation$340,987

UH3 · FY2022 · CA

Colorectal Cancer Molecular Subtype Assay Development and Validation$297,095

UH3 · FY2021 · CA

Colorectal Cancer Molecular Subtype Assay Development and Validation$163,706

UH2 · FY2019 · CA

Colorectal Cancer Molecular Subtype Assay Development and Validation$214,027

UH2 · FY2018 · CA